UroGen Pharma Ltd (NAS:URGN)
$ 13.05 -0.76 (-5.5%) Market Cap: 549.59 Mil Enterprise Value: 437.91 Mil PE Ratio: 0 PB Ratio: 18.74 GF Score: 72/100

Urogen Pharma Ltd at Ladenburg Thalmann Virtual Healthcare Conference Transcript

Jul 14, 2021 / 04:00PM GMT
Release Date Price: $15.47 (+2.65%)
Matthew Kaplan
Ladenburg Thalmann & Co., Inc. - Analyst

It's my pleasure to introduce our next presenting company, UroGen Pharma. Presenting for UroGen Pharma today is the CEO, Liz Barrett. Liz, thank you for joining us at the conference today. And I will hand the podium over to you, and hopefully we have some time for a little bit of questions after your presentation.

Liz Barrett
UroGen Pharma Ltd. - President and CEO

Great. Sounds good. It's good to see you, Matt. And I hear you are in the office, so great to see things getting somewhat back to normal, right? I will try to run through the slides very quickly. So I apologize for anyone if it seems I'm going fast, but I do think it would be great for us to spend a few minutes in Q&A.

And I'm excited to be here to present on behalf of UroGen Pharma. Of course, our requisite forward-looking statement.

For those of you who are not familiar with our Company, it's really important to understand where we started and the roots of the Company. How we got started, how we are here today is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot